The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …

Monoclonal antibody-based treatment of cancer has been established as one of the most
successful therapeutic strategies for both hematologic malignancies and solid tumors in the …

Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating
the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of …

The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of
antibody conjugates. To assess the impact of the conjugation site, we engineered cysteines …

Antibody-drug conjugates (ADCs) allow selective targeting of cytotoxic drugs to cancer cells
presenting tumor-associated surface markers, thereby minimizing systemic toxicity …

Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-
DM1), which combines human epidermal growth factor receptor 2 (HER2)–targeted delivery …

Therapeutic monoclonal antibody (TMA) based therapies for cancer have advanced
significantly over the past two decades both in their molecular sophistication and clinical …

Conventional anticancer therapeutics often suffer from lack of specificity, resulting in poor
therapeutic indexes and substantial toxicities to normal healthy tissues. Monoclonal …

Abstract Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate
comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound …

Abstract Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of the
anti-HER2 antibody trastuzumab linked via a nonreducible thioether linker to the …